Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 49

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 49
---
’ s E VO+ lens – its first new lens in China in over ten years – will serve as a catalyst for growth and market share gains in the Chinese market Market Leadership ▪ Myopia affects approximately three billion people worldwide, and its prevalence is expected to grow significantly over the co min g decades due to elevated use of computers and smartphones and diminished exposure to natural light Long - Term Demand Tailwinds ▪ STAAR has nearly $200 million in cash and no debt, and therefore no evident need for near - term financing ▪ STAAR’s ample cash balance and $30 million share repurchase authorization provide flexibility for the Company to support the sto ck in the event of near - term price dislocation if the Proposed Merger is not approved Pristine Balance Sheet and Ample Liquidity ▪ The Company has been cutting costs and expects to exit 2025 having reduced its SG&A expense base by at least 11%, supporting mar gin expansion amid accelerating growth and expanded production ▪ We see an opportunity to further reduce SG&A expenses, particularly in the U.S., without impacting revenue ▪ We believe there is an opportunity to enhance gross margin by localizing manufacturing and moving to “tier 1” distributors in Ch ina Enhanced Organizational Efficiency ▪ The level of inventory owned by STAAR’s distributors in China has decreased substantially and has returned to historical leve ls Normalized Inventory Levels ▪ Management’s projections forecast that STAAR will not only return to growth but achieve record levels of net sales and Adjust ed EBITDA within the next 18 months ▪ The Company projects net sales to compound at a rate of 10% annually from 2026 to 2030, demonstrating the long - term opportunity for growth Clear Path to Growth and Profitability

Broadwood Partners, L.P. Conclusion 70 We urge stockholders to vote against the Proposed Merger using the GREEN proxy card GREEN 1. Source: FactSet, STAAR Press Release, February 11, 2025. 2. Source: STAAR proxy statement on Form DEFM14A, filed with the SEC on September 16, 2025. The Wrong Price The Wrong Process The Wrong Time ▪ In our view, the purchase price of $28 per share significantly undervalues STAAR, representing a substantial discount to intrinsic value ▪ STAAR’s strategic value to Alcon is significant, and there are material cost savings and potential revenue synergies; notably, less than a year ago, Alcon offered much more for STAAR,